合并与不合并COVID-19肺炎的衰弱危重患者治疗限制与临床结局
该注册登记的多中心回顾性队列研究纳入澳大利亚和新西兰129个ICU的884例衰弱成人(CFS≥5),比较COVID-19相关与非COVID-19病毒性肺炎或ARDS患者的治疗限制情况。结果显示两组治疗限制比例相似(35.8% vs 36.1%,p=0.92),衰弱程度增加、年龄增长和慢性呼吸系统疾病是治疗限制的独立预测因素,而COVID-19本身不影响治疗限制。
要点
- 衰弱危重患者中36.0%存在治疗限制,COVID-19组与非COVID-19组比例无差异。
- 衰弱程度每增加一级,治疗限制风险增加(OR=1.72,95%CI 1.39-2.14)。
- 年龄增长和慢性呼吸系统疾病也增加治疗限制可能性,COVID-19本身无独立影响。
核心结论
- 在ICU入院的衰弱成人中,合并与不合并COVID-19肺炎者的治疗限制比例相似,COVID-19本身不影响治疗限制的设立。
研究设计与样本
- 基于注册登记的多中心回顾性队列研究,纳入2020年1月1日至2021年12月31日两年间澳大利亚和新西兰129个公立和私立ICU中所有≥16岁、有CFS评分记录、入院诊断编码为病毒性肺炎或ARDS的衰弱成人(CFS≥5)。
主要发现
- 最终分析纳入884例衰弱患者,其中369例(41.7%)确诊COVID-19。
- COVID-19组男性比例更高(55.3% vs 47.0%;p=0.015),两组年龄和APACHE-III评分无差异。
- 总体36.0%(318/884)存在治疗限制,两组相似(35.8% [132/369] vs 36.1% [186/515];p=0.92)。
- 校正混杂因素后,衰弱程度增加(OR=1.72;95%CI 1.39-2.14)、年龄(OR=1.05;95%CI 1.04-1.06)和慢性呼吸系统疾病(OR=1.58;95%CI 1.10-2.27)增加治疗限制的可能性。
- COVID-19本身不影响治疗限制(OR=1.39;95%CI 0.98-1.96)。
关键数值与推荐
- 衰弱定义为CFS≥5。
- 治疗限制总体发生率为36.0%(318/884)。
- 衰弱程度与治疗限制的校正OR=1.72(95%CI 1.39-2.14)。
- 年龄与治疗限制的校正OR=1.05(95%CI 1.04-1.06)。
- 慢性呼吸系统疾病与治疗限制的校正OR=1.58(95%CI 1.10-2.27)。
临床怎么用
- 对ICU入院的衰弱患者应常规评估CFS,衰弱程度越高越需早期讨论治疗限制。
- COVID-19诊断本身不应作为设立治疗限制的主要依据,应综合衰弱程度、年龄和慢性呼吸系统疾病等条件判断。
局限性
- 本研究为回顾性队列研究,可能存在未测量混杂因素。
- 仅纳入有CFS评分记录的患者,可能存在选择偏倚。
- 研究局限于澳大利亚和新西兰ICU,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The presence of treatment limitations in patients with frailty at intensive care unit (ICU) admission is unknown. We aimed to evaluate the presence and predictors of treatment limitations in patients with and without COVID-19 pneumonitis in those admitted to Australian and New Zealand ICUs. METHODS: This registry-based multicenter, retrospective cohort study included all frail adults (≥16 years) with documented clinical frailty scale (CFS) scores, admitted to ICUs with admission diagnostic codes for viral pneumonia or acute respiratory distress syndrome (ARDS) over 2 years between January 01, 2020 and December 31, 2021. Frail patients (CFS ≥5) coded as having viral pneumonitis or ARDS due to COVID-19 were compared to those with other causes of viral pneumonitis or ARDS for documented treatment limitations. RESULTS: 884 frail patients were included in the final analysis from 129 public and private ICUs. 369 patients (41.7%) had confirmed COVID-19. There were more male patients in COVID-19 (55.3% vs 47.0%; p = 0.015). There were no differences in age or APACHE-III scores between the two groups. Overall, 36.0% (318/884) had treatment limitations, but similar between the two groups (35.8% [132/369] vs 36.1% [186/515]; p = 0.92). After adjusting for confounders, increasing frailty (OR = 1.72; 95%-CI 1.39-2.14), age (OR = 1.05; 95%-CI 1.04-1.06), and presence of chronic respiratory condition (OR = 1.58; 95%-CI 1.10-2.27) increased the likelihood of instituting treatment limitations. However, the presence of COVID-19 by itself did not influence treatment limitations (odds ratio [OR] = 1.39; 95%-CI 0.98-1.96). CONCLUSIONS: The proportion of treatment limitations was similar in patients with frailty with or without COVID-19 pneumonitis at ICU admission.
引用
- Subramaniam A, Tiruvoipati R, Pilcher D, et al. Treatment limitations and clinical outcomes in critically ill frail patients with and without COVID-19 pneumonitis. J Am Geriatr Soc. 2022. PMID: 36151970. doi:10.1111/jgs.18044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。